Drug Type Immune stimulating antibody conjugate (ISAC) |
Synonyms CEA ISAC(Bolt Biotherapeutics) |
Target |
Action antagonists, agonists |
Mechanism CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists), TLR7 agonists(Toll like receptor 7 agonists), TLR8 agonists(Toll like receptor 8 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Preclinical | United States | 01 May 2025 | |
Colorectal Cancer | Preclinical | United States | 30 Apr 2025 | |
Pancreatic Cancer | Preclinical | United States | 30 Apr 2025 |